이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Godavari Drugs 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mukund Kakani

최고 경영자

₹1.7m

총 보상

CEO 급여 비율	100.0%
CEO 임기	no data
CEO 소유권	20.0%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	10.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Mukund Kakani 의 보수는 Godavari Drugs 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	₹55m
Dec 31 2023	n/a	n/a	₹42m
Sep 30 2023	n/a	n/a	₹37m
Jun 30 2023	n/a	n/a	₹37m
Mar 31 2023	₹2m	₹2m	₹38m
Dec 31 2022	n/a	n/a	₹37m
Sep 30 2022	n/a	n/a	₹44m
Jun 30 2022	n/a	n/a	₹47m
Mar 31 2022	₹1m	₹1m	₹52m
Dec 31 2021	n/a	n/a	₹53m
Sep 30 2021	n/a	n/a	₹49m
Jun 30 2021	n/a	n/a	₹47m
Mar 31 2021	₹1m	₹1m	₹41m
Dec 31 2020	n/a	n/a	₹36m
Sep 30 2020	n/a	n/a	₹31m
Jun 30 2020	n/a	n/a	₹24m
Mar 31 2020	₹1m	₹1m	₹20m
Dec 31 2019	n/a	n/a	₹16m
Sep 30 2019	n/a	n/a	₹15m
Jun 30 2019	n/a	n/a	₹15m
Mar 31 2019	₹1m	₹1m	₹12m
Dec 31 2018	n/a	n/a	₹12m
Sep 30 2018	n/a	n/a	₹10m
Jun 30 2018	n/a	n/a	₹9m
Mar 31 2018	₹1m	₹1m	₹8m

보상 대 시장: Mukund 의 총 보상 ($USD 20.37K ) Indian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 38.49K ).

보상과 수익: Mukund 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Mukund Kakani (72 yo)

no data

테뉴어

₹1,701,000

보상

Mr. Mukund Kakani serves as the Chief Executive Officer, Managing Director and Director of Godavari Drugs Ltd.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mukund Kakani	CEO, MD & Director	no data	₹1.70m	19.99% ₹ 156.5m
Mohit Jaju	CFO & Whole Time Director	12.2yrs	₹1.65m	7.1% ₹ 55.6m
Syed Hussain	Non-Executive Independent Director	18.6yrs	₹80.00k	데이터 없음
Ghanshyam Jaju	Chairman	17.8yrs	데이터 없음	16.76% ₹ 131.3m
Vimala Madon	Non-Executive Independent Director	9.3yrs	₹80.00k	데이터 없음
Mahendra Bhalerao	Non-Executive Independent Director	1.7yrs	₹20.00k	0.020% ₹ 156.0k
Dinesh Udpa	Additional Non-Executive Independent Director	less than a year	데이터 없음	데이터 없음

10.8yrs

평균 재임 기간

74.5yo

평균 연령

경험이 풍부한 이사회: 530317 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.7 년).

Godavari Drugs 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Godavari Drugs Limited, Annual General Meeting, Aug 29, 2024

Godavari Drugs Limited Announces Resignation of Ramesh Babu Telugu from the Post of Independent Director

Godavari Drugs Limited, Annual General Meeting, Aug 12, 2023

Godavari Drugs Limited Approves the Appointment of Mr. Venkatesh Achanta as Company Secretary

Godavari Drugs Limited Announces Resignation of Mrs. Rashmi Agarwal as Company Secretary and Compliance Officer

Insider recently sold ₹4.4m worth of stock

Recent updates

Full year 2024 earnings released: EPS: ₹7.37 (vs ₹5.03 in FY 2023)

Godavari Drugs Limited, Annual General Meeting, Aug 29, 2024

Godavari Drugs Limited to Report Q4, 2024 Results on May 30, 2024

Godavari Drugs Limited to Report Q4, 2024 Results on May 30, 2024

Third quarter 2024 earnings released: EPS: ₹1.62 (vs ₹0.89 in 3Q 2023)

Godavari Drugs Limited to Report Q3, 2024 Results on Feb 13, 2024

Godavari Drugs Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: EPS: ₹1.14 (vs ₹1.15 in 2Q 2023)

Investor sentiment improves as stock rises 17%

Godavari Drugs Limited Announces Resignation of Ramesh Babu Telugu from the Post of Independent Director

Godavari Drugs Limited to Report Q1, 2024 Results on Aug 11, 2023

Godavari Drugs Limited, Annual General Meeting, Aug 12, 2023

Full year 2023 earnings released: EPS: ₹5.03 (vs ₹6.97 in FY 2022)

Investor sentiment improves as stock rises 20%

Godavari Drugs Limited Approves the Appointment of Mr. Venkatesh Achanta as Company Secretary

Godavari Drugs Limited to Report Q4, 2023 Results on May 29, 2023

Third quarter 2023 earnings released: EPS: ₹0.89 (vs ₹1.77 in 3Q 2022)

Godavari Drugs Limited Announces Resignation of Mrs. Rashmi Agarwal as Company Secretary and Compliance Officer

Godavari Drugs Limited to Report Q3, 2023 Results on Feb 14, 2023

Insider recently sold ₹4.4m worth of stock

Godavari Drugs Limited Appoints Mahendra Uday Bhalerao as Non-Executive Independent Director

Investor sentiment improved over the past week

Insider recently sold ₹499k worth of stock

Insufficient new directors

Godavari Drugs Limited Approves the Appointment of Mahindra Uday Bhalerao as Additional Independent Director

Godavari Drugs Limited Announces Resignation of Mr. Dilip Keshavlal Patel from Post of Non-Executive Independent Director

Godavari Drugs Limited to Report Q2, 2023 Results on Nov 12, 2022

Insider recently sold ₹395k worth of stock

First quarter 2023 earnings released: EPS: ₹1.22 (vs ₹1.89 in 1Q 2022)

Godavari Drugs Limited to Report Q1, 2023 Results on Aug 13, 2022

Investor sentiment deteriorated over the past week

Insufficient new directors

Godavari Drugs Limited Announces Resignation of Kirti Kumar Jain from the CFO

Full year 2022 earnings released: EPS: ₹6.97 (vs ₹5.48 in FY 2021)

Godavari Drugs Limited to Report Q4, 2022 Results on Apr 19, 2022

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Godavari Drugs Limited to Report Q3, 2022 Results on Feb 14, 2022

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹5.48 (vs ₹2.66 in FY 2020)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹5.48 (vs ₹2.66 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹48.10

Third quarter 2021 earnings released: EPS ₹1.33 (vs ₹0.72 in 3Q 2020)

Godavari Drugs Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹45.90

Investor sentiment improved over the past week

First quarter earnings released

Godavari Drugs Limited to Report Q1, 2021 Results on Aug 13, 2020

New 90-day high - ₹38.25

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령